

Interventional Cardiology Devices Market by Type (Stents, Structural Heart Devices, Angioplasty Balloons (Drug-Eluting), Angiography Catheters, Plaque Modification Devices (Thrombectomy Devices), Guidewires, Introducer Sheaths) - Global Forecast to 2029

Market Report | 2024-12-19 | 368 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global interventional cardiology devices market is projected to reach USD 27.80 billion in 2024 and is projected to reach USD 37.27 billion by 2029, at a CAGR of 6.0% during the forecast period.

The growth of the interventional cardiology devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes. As rates of heart disease, hypertension, and diabetes rise, the need for effective treatments such as angioplasty, stenting, and valve replacements also increases. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market's growth.

"Based on the angioplasty balloons type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market."

Traditional angioplasty balloons, also known as plain old balloon angioplasty (POBA), offer several advantages over drug-eluting balloons (DEBs) in certain clinical scenarios. First, traditional balloons tend to be less costly than DEBs, making them a more accessible option for healthcare systems and patients, especially in regions with limited healthcare budgets or where reimbursement policies may not fully cover DEB, also POBA also has a simpler mechanism-it dilates narrowed blood vessels by compressing plaque against the vessel walls without releasing drugs, which can be beneficial in cases where the risks associated

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

with drug delivery aren't justified. For example, in acute settings like treating certain types of arterial blockages where drug-delivery isn't critical to outcomes, POBA may provide sufficient clinical results without the added complexity or cost of drug elution.

"The embolic protection devices segment in hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."

Embolism protection devices (EPDs) are a vital advancement in interventional cardiology, designed to capture and remove debris that may dislodge during vascular procedures, thereby minimizing the risk of embolization. These devices are particularly beneficial during interventions like carotid artery stenting, where dislodged particles could travel to the brain and cause strokes. By capturing such debris, EPDs significantly reduce periprocedural stroke risks and improve the safety profile of these interventions.

"The guidewires segment in other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."

Guidewires are essential in interventional cardiology, offering precision, flexibility, and control that enhance the safety and effectiveness of procedures like angioplasty and stent placement. These thin, flexible wires guide catheters through blood vessels, allowing clinicians to navigate complex vascular structures and reach targeted areas with minimal trauma to surrounding tissues. Their superior torque response and maneuverability help cardiologists access difficult-to-reach lesions, improving procedural success rates and reducing the need for open surgery.

"Based on the end user, hospitals segment is expected to grow by the highest CAGR in the interventional cardiology devices market."

Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are carried out in hospitals because they boast special facilities and the sophisticated imaging technologies that would treat a patient with maximum quality. They are well equipped both for simple and complicated processes with a good staff; besides, they are where they can be managed whenever a complication arises. These settings enable cardiologists to take the latest tool systems into practice, including drug-eluting stents, rotational atherectomy and intravascular ultrasound, to ensure utmost precision and safety for patients.

"Asia Pacific to grow with the highest CAGR in the interventional cardiology devices market during the forecast period."

The Asia-Pacific region is also expected to experience maximum growth in the interventional cardiology devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.

The break up of the profile of primary participants in the interventional cardiology devices market:

-□By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%

-□By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.

-□By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

Key players in the interventional cardiology devices market

Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmbH (Germany), Medinol Ltd (Turkey), Welling (Netherlands), Balton SP (Poland), Translumina (India).

Research Coverage:

The report analyzes the interventional cardiology devices market and aims at estimating the market size and future growth potential of this market based on various segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user. The report also includes a product portfolio matrix of various interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional cardiology devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

- Of Analysis of key drivers (growing prevalence of cardiovascular diseases, technological advancements in interventional cardiology procedures, increased prevalence of diabetes & growing product launches by leading players in developing countries), restraints (availability of alternative treatments & recall of products by industry participants to limit the uptake of interventional cardiology equipment), opportunities (high growth potential in emerging markets & growing coronary stent demand in developing countries) and challenges (stringent regulatory requirements delaying the approval of cardiac devices).
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional cardiology devices market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global interventional cardiology devices market
- Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user.
- Market Diversification: Exhaustive information about new product and services or product and service enhancements, growing geographies, recent developments, and investments in the global interventional cardiology devices market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global interventional cardiology devices market.

Table of Contents:

1□INTRODUCTION□	29
1.1□STUDY OBJECTIVES□	29
1.2□MARKET DEFINITION□	29
1.3□MARKET SCOPE□	29
1.3.1□MARKET SEGMENTATION□	30
1.3.2□INCLUSIONS & EXCLUSIONS□	31
1.3.3□YEARS CONSIDERED□	31
1.3.4□CURRENCY CONSIDERED□	31
1.4□MARKET STAKEHOLDERS□	32
1.5□LIMITATIONS□	32

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.6	SUMMARY OF CHANGES	32
2	RESEARCH METHODOLOGY	34
2.1	INTRODUCTION	34
2.1.1	SECONDARY RESEARCH	35
2.1.2	KEY DATA FROM SECONDARY SOURCES	36
2.1.2.1	Primary data	36
2.1.3	KEY DATA FROM PRIMARY SOURCES	38
2.1.3.1	Insights from primary experts	39
2.2	MARKET SIZE ESTIMATION	41
2.3	DATA TRIANGULATION APPROACH	47
2.4	MARKET SHARE ANALYSIS	47
2.5	STUDY ASSUMPTIONS	48
2.6	RESEARCH LIMITATIONS	48
2.6.1	METHODOLOGY-RELATED LIMITATIONS	48
2.7	RISK ASSESSMENT	49
3	EXECUTIVE SUMMARY	50
4	PREMIUM INSIGHTS	56
4.1	INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW	56
4.2	ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER	57
4.3	INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	58
4.4	REGIONAL MIX: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2022-2029)	59
?		
5	MARKET OVERVIEW	60
5.1	INTRODUCTION	60
5.2	MARKET DYNAMICS	60
5.2.1	DRIVERS	61
5.2.1.1	Growing prevalence of cardiovascular diseases	61
5.2.1.2	Rising technological investments in interventional cardiology procedures	62
5.2.1.3	Increasing prevalence of diabetes	63
5.2.1.4	Favorable regulatory support	63
5.2.2	RESTRAINTS	64
5.2.2.1	Availability of alternative treatments	64
5.2.2.2	Product recalls	65
5.2.3	OPPORTUNITIES	65
5.2.3.1	High growth potential in emerging markets	65
5.2.3.2	Increasing demand for coronary stents	66
5.2.4	CHALLENGES	67
5.2.4.1	Stringent regulatory requirements for product approvals	67
5.3	INDUSTRY TRENDS	68
5.3.1	DRUG-ELUTING TECHNOLOGIES	68
5.3.2	INCREASING EMPHASIS ON MINIMALLY INVASIVE PROCEDURES	68
5.4	SUPPLY CHAIN ANALYSIS	69
5.5	VALUE CHAIN ANALYSIS	71
5.6	TECHNOLOGY ANALYSIS	72
5.6.1	KEY TECHNOLOGIES	72
5.6.1.1	TAVR technology	72
5.6.2	ADJACENT TECHNOLOGIES	73

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6.3	COMPLEMENTARY TECHNOLOGIES	74
5.6.3.1	Integration of real-time monitoring into wearable technologies	74
5.6.3.2	Precise cardiovascular interventions through artificial intelligence	75
5.7	PORTER'S FIVE FORCES ANALYSIS	76
5.7.1	THREAT OF NEW ENTRANTS	77
5.7.2	THREAT OF SUBSTITUTES	77
5.7.3	BARGAINING POWER OF SUPPLIERS	77
5.7.4	BARGAINING POWER OF BUYERS	77
5.7.5	INTENSITY OF COMPETITIVE RIVALRY	78
5.8	REGULATORY LANDSCAPE	78
5.8.1	REGULATORY ANALYSIS	78
5.8.1.1	North America	78
5.8.1.1.1	US	78
5.8.1.2	Europe	79
5.8.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	80
5.9	PRICING ANALYSIS	83
5.9.1	INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT TYPE, 2023	83
5.9.2	INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023	84
5.9.3	INDICATIVE AVERAGE SELLING PRICE, BY REGION	84
5.10	ECOSYSTEM ANALYSIS	85
5.11	PATENT ANALYSIS	87
5.11.1	PATENT PUBLICATION TRENDS FOR INTERVENTIONAL CARDIOLOGY DEVICES	87
5.11.2	INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS	87
5.12	TRADE ANALYSIS	90
5.12.1	TRADE ANALYSIS FOR INTERVENTIONAL CARDIOLOGY DEVICES AND CONSUMABLES	90
5.12.2	HS CODES	90
5.13	KEY CONFERENCES & EVENTS, 2024-2025	92
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	93
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	93
5.14.2	BUYING CRITERIA	94
5.15	UNMET NEEDS/END-USER EXPECTATIONS	95
5.16	IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET	96
5.17	CASE STUDY ANALYSIS	96
5.17.1	CASE STUDY 1: BOSTON SCIENTIFIC CORPORATION USES GUIDEZILLA II EXTENSION CATHETER FOR PC INTERVENTIONS	96
5.17.2	CASE STUDY 2: MEDTRONIC PROVIDES CARDIOLOGY DEVICES FOR VENOUS INTERVENTIONS	97
5.17.3	CASE STUDY 3: ABBOTT OFFERS DRUG-ELUTING STENTS FOR PATIENTS WITH HIGHER RISK OF STROKE	97
5.18	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	98
5.19	ADJACENT MARKETS FOR INTERVENTIONAL CARDIOLOGY DEVICES	99
5.20	INVESTMENT & FUNDING SCENARIO	99
6	ANGIOPLASTY STENTS MARKET, BY TYPE	100
6.1	INTRODUCTION	101
6.1.1	DRUG-ELUTING STENTS	103
6.1.1.1	Drug-eluting stents to hold largest share of angioplasty stents market	103
6.1.2	BARE-METAL STENTS	105
6.1.2.1	Increasing use of drug-eluting stents to limit growth of bare-metal stents market	105
6.1.3	BIOABSORBABLE STENTS	107
6.1.3.1	Ability of bioabsorbable stents to ensure complete healing of arteries to propel demand	107

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

?

7 STRUCTURAL HEART DEVICES MARKET, BY TYPE 109

7.1 INTRODUCTION 110

7.1.1 AORTIC VALVE THERAPY DEVICES 111

7.1.1.1 Increasing prevalence of aortic valve stenosis to support market growth 111

7.1.2 OTHER THERAPY DEVICES 113

8 CATHETERS MARKET, BY TYPE 116

8.1 INTRODUCTION 117

8.1.1 ANGIOGRAPHY CATHETERS 119

8.1.1.1 Rising cases of artery disease and heart attacks to propel market 119

8.1.2 GUIDING CATHETERS 121

8.1.2.1 Increasing number of angiography procedures to drive the market 121

8.1.3 IVUS/OCT CATHETERS 123

8.1.3.1 Ability to obtain 3D images for aneurysm assessment to support market growth 123

9 ANGIOPLASTY BALLOONS MARKET, BY TYPE 126

9.1 INTRODUCTION 127

9.1.1 OLD/NORMAL BALLOONS 128

9.1.1.1 Low treatment costs associated with old/normal balloons to drive growth 128

9.1.2 DRUG-ELUTING BALLOONS 130

9.1.2.1 Rising number of regulatory approvals for drug-eluting balloons to support market growth during forecast period 130

9.1.3 CUTTING/SCORING BALLOONS 132

9.1.3.1 Limited use of cutting balloon-aided procedures to restrain market growth 132

10 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 134

10.1 INTRODUCTION 135

10.1.1 THROMBECTOMY DEVICES 137

10.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market 137

10.1.2 ATHERECTOMY DEVICES 138

10.1.2.1 Increasing use of lipid-modifying drugs for atherosclerosis to support market growth 138

11 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 140

11.1 INTRODUCTION 141

11.1.1 EMBOLIC PROTECTION DEVICES 142

11.1.1.1 Adoption of filter & occlusion-based devices to propel market 142

11.1.2 CHRONIC TOTAL OCCLUSION DEVICES 144

11.1.2.1 Uptake in treatment of total occlusions to drive market 144

12 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE 145

12.1 INTRODUCTION 146

12.1.1 GUIDEWIRES 147

12.1.1.1 Growing demand for stent placements and coronary intervention procedures to propel market 147

12.1.2 VASCULAR CLOSURE DEVICES 149

12.1.2.1 Ability to provide increased efficacy in patient outcomes to fuel uptake 149

12.1.3 INTRODUCER SHEATHS 150

12.1.3.1 Ability to provide secure access to blood vessels to support market growth 150

12.1.4 BALLOON INFLATION DEVICES 151

12.1.4.1 Increasing incidence of peripheral artery disease to drive market 151

12.1.5 HEMOSTASIS HEART VALVES 153

12.1.5.1 Growing focus on precision medicine 153

13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER 154

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1	INTRODUCTION	155
13.2	HOSPITALS	155
13.2.1	AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET	155
13.3	AMBULATORY SURGERY CENTERS	157
13.3.1	LOW CASES OF HAIS AND SHORTER RECOVERY TIMES TO PROPEL MARKET	157
13.4	OTHER END USERS	159
14	INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION	160
14.1	INTRODUCTION	161
14.2	NORTH AMERICA	162
14.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	162
14.2.2	US	167
14.2.2.1	Availability of reimbursements for cardiology procedures to drive market	167
14.2.3	CANADA	171
14.2.3.1	Rising prevalence of chronic diseases to drive market	171
14.3	EUROPE	175
14.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	176
14.3.2	GERMANY	180
14.3.2.1	Growing hub for advanced technology product distributors to drive market	180
14.3.3	FRANCE	184
14.3.3.1	Favorable government initiatives in France to support market growth	184
14.3.4	UK	188
14.3.4.1	Growing focus on personalized medicine to fuel uptake	188
?		
14.3.5	ITALY	192
14.3.5.1	Increasing cases of obesity and CVD to support market growth	192
14.3.6	SPAIN	196
14.3.6.1	Increasing prevalence of age-related CVD conditions to drive market	196
14.3.7	REST OF EUROPE	200
14.4	ASIA PACIFIC	204
14.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	204
14.4.2	CHINA	209
14.4.2.1	High tobacco consumption and increasing cases of CVD to fuel uptake	209
14.4.3	JAPAN	213
14.4.3.1	Increasing demand for stents and catheters to support market growth	213
14.4.4	INDIA	217
14.4.4.1	Improvements in angioplasty devices to fuel uptake	217
14.4.5	AUSTRALIA	221
14.4.5.1	Increasing cases of lifestyle disorders to support market growth	221
14.4.6	SOUTH KOREA	225
14.4.6.1	Growth in pharmaceutical sectors to propel market	225
14.4.7	REST OF ASIA PACIFIC	229
14.5	LATIN AMERICA	233
14.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	233
14.5.2	BRAZIL	237
14.5.2.1	Rising demand for quality treatment and focus on growing healthcare infrastructure to drive market	237
14.5.3	MEXICO	241
14.5.3.1	Increasing cases of diabetes to fuel market	241

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.5.4	REST OF LATIN AMERICA	245
14.6	MIDDLE EAST & AFRICA	249
14.6.1	MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK	249
14.6.2	GCC COUNTRIES	253
14.6.3	REST OF MIDDLE EAST & AFRICA	257
15	COMPETITIVE LANDSCAPE	262
15.1	OVERVIEW	262
15.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	262
15.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET	263
15.3	REVENUE ANALYSIS	264
15.4	MARKET SHARE ANALYSIS	265
15.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	268
15.5.1	STARS	268
15.5.2	EMERGING LEADERS	268
15.5.3	PERVASIVE PLAYERS	268
15.5.4	PARTICIPANTS	268
15.6	COMPANY FOOTPRINT	270
15.6.1	COMPANY FOOTPRINT: KEY PLAYERS, 2023	270
15.6.1.1	Company footprint	270
15.6.1.2	Region footprint	271
15.6.1.3	Product footprint	272
15.6.1.4	Angioplasty stents footprint	274
15.6.1.5	Structural heart devices footprint	275
15.6.1.6	Catheters footprint	276
15.6.1.7	Angioplasty balloons footprint	277
15.6.1.8	Plaque modification devices footprint	278
15.6.1.9	Hemodynamic flow alteration devices footprint	279
15.6.1.10	Other interventional cardiology devices footprint	280
15.6.1.11	End-user footprint	281
15.7	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	282
15.7.1	PROGRESSIVE COMPANIES	282
15.7.2	RESPONSIVE COMPANIES	282
15.7.3	DYNAMIC COMPANIES	282
15.7.4	STARTING BLOCKS	282
15.7.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	284
15.8	COMPANY VALUATION & FINANCIAL METRICS	286
15.8.1	FINANCIAL METRICS	286
15.8.2	COMPANY VALUATION	286
15.9	BRAND/PRODUCT COMPARATIVE ANALYSIS	287
15.10	R&D ASSESSMENT OF KEY PLAYERS	288
15.11	COMPETITIVE SCENARIO	288
15.11.1	PRODUCT LAUNCHES & APPROVALS	288
15.11.2	DEALS	289
15.11.3	EXPANSIONS	290
16	COMPANY PROFILES	291
16.1	KEY PLAYERS	291
16.1.1	BOSTON SCIENTIFIC CORPORATION	291

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.1.1.1	Business overview	291
16.1.1.2	Products offered	292
16.1.1.3	Recent developments	295
16.1.1.3.1	Product launches & approvals	295
16.1.1.3.2	Deals	296
16.1.1.4	MnM view	297
16.1.1.4.1	Key strengths	297
16.1.1.4.2	Strategic choices	297
16.1.1.4.3	Weaknesses & competitive threats	297
16.1.2	MEDTRONIC	298
16.1.2.1	Business overview	298
16.1.2.2	Products offered	299
16.1.2.3	Recent developments	302
16.1.2.3.1	Product launches & approvals	302
16.1.2.3.2	Deals	303
16.1.2.4	MnM view	303
16.1.2.4.1	Key strengths	303
16.1.2.4.2	Strategic choices	303
16.1.2.4.3	Weaknesses & competitive threats	303
16.1.3	ABBOTT	304
16.1.3.1	Business overview	304
16.1.3.2	Products offered	305
16.1.3.3	Recent developments	307
16.1.3.3.1	Product launches & approvals	307
16.1.3.3.2	Deals	308
16.1.3.4	MnM view	308
16.1.3.4.1	Key strengths	308
16.1.3.4.2	Strategic choices	308
16.1.3.4.3	Weaknesses & competitive threats	308
16.1.4	KONINKLIJKE PHILIPS N.V.	309
16.1.4.1	Business overview	309
16.1.4.2	Products offered	310
16.1.4.3	Recent developments	311
16.1.4.3.1	Deals	311
16.1.5	TERUMO CORPORATION	312
16.1.5.1	Business overview	312
16.1.5.2	Products offered	313
16.1.5.3	Recent developments	315
16.1.5.3.1	Product launches	315
16.1.5.3.2	Expansions	315
16.1.5.4	MnM view	315
16.1.5.4.1	Key strengths	315
16.1.5.4.2	Strategic choices	315
16.1.5.4.3	Weaknesses & competitive threats	316
16.1.6	EDWARDS LIFESCIENCES CORPORATION	317
16.1.6.1	Business overview	317
16.1.6.2	Products offered	318

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1.6.3 Recent developments 319
- 16.1.6.3.1 Product launches & approvals 319
- 16.1.6.3.2 Deals 320
- ?
- 16.1.7 B. BRAUN SE 321
- 16.1.7.1 Business overview 321
- 16.1.7.2 Products offered 322
- 16.1.7.3 Recent developments 324
- 16.1.7.3.1 Product launches & approvals 324
- 16.1.7.3.2 Deals 324
- 16.1.8 INTEGER HOLDINGS CORPORATION 325
- 16.1.8.1 Business overview 325
- 16.1.8.2 Products offered 326
- 16.1.8.3 Recent developments 327
- 16.1.8.3.1 Deals 327
- 16.1.8.3.2 Expansions 328
- 16.1.9 TELEFLEX INCORPORATED 329
- 16.1.9.1 Business overview 329
- 16.1.9.2 Products offered 330
- 16.1.9.3 Recent developments 331
- 16.1.9.3.1 Product approvals 331
- 16.1.10 PENUMBRA, INC. 333
- 16.1.10.1 Business overview 333
- 16.1.10.2 Products offered 334
- 16.1.10.3 Recent developments 335
- 16.1.10.3.1 Product launches & approvals 335
- 16.1.11 COOK 336
- 16.1.11.1 Business overview 336
- 16.1.11.2 Products offered 336
- 16.1.11.3 Recent developments 338
- 16.1.11.3.1 Deals 338
- 16.1.12 CORDIS 339
- 16.1.12.1 Business overview 339
- 16.1.12.2 Products offered 339
- 16.1.12.3 Recent developments 340
- 16.1.12.3.1 Product launches & approvals 340
- 16.1.12.3.2 Deals 340
- 16.1.13 IVASCULAR S.L.U. 341
- 16.1.13.1 Business overview 341
- 16.1.13.2 Products offered 341
- 16.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD. 342
- 16.1.14.1 Business overview 342
- 16.1.14.2 Products offered 342
- 16.1.14.3 Recent developments 343
- 16.1.14.3.1 Product launches 343
- ?
- 16.1.15 BIOTRONIK SE & CO. KG 344

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.1.15.1	Business overview	344
16.1.15.2	Products offered	344
16.1.15.3	Recent developments	345
16.1.15.3.1	Product launches	345
16.2	OTHER PLAYERS	346
16.2.1	AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL)	346
16.2.2	ENDOCOR GMBH & CO. KG	347
16.2.3	INSITU TECHNOLOGIES, INC.	348
16.2.4	MERIL LIFE SCIENCES PVT. LTD	349
16.2.5	ALVIMEDICA	350
16.2.6	CARDIONOVUM GMBH	351
16.2.7	MEDINOL	352
16.2.8	WELLINQ	353
16.2.9	BALTON SP.	354
16.2.10	TRANSLUMINA	355
17	APPENDIX	356
17.1	DISCUSSION GUIDE	356
17.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	362
17.3	CUSTOMIZATION OPTIONS	364
17.4	RELATED REPORTS	364
17.5	AUTHOR DETAILS	365

Interventional Cardiology Devices Market by Type (Stents, Structural Heart Devices, Angioplasty Balloons (Drug-Eluting), Angiography Catheters, Plaque Modification Devices (Thrombectomy Devices), Guidewires, Introducer Sheaths) - Global Forecast to 2029

Market Report | 2024-12-19 | 368 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature